Prevention of RSV Disease in Healthy Infants Take Home Point: In this early phase, drug-manufacturer-funded clinical trial, a single dose of clesrovimab reduced the incidence of respiratory syncytial virus (RSV)-associated medically attended lower respiratory infection and RSV-associated hospitalization, with a safety profile similar to that of a placebo. Citation: Zar HJ, Simões E, Madhi S, et. al. Clesrovimab in Infants and Children at Increased Risk for Severe RSV Disease. New Eng J Med. 2025:393, 13;1292-1303. …
Read More